Kevin Lind is a seasoned biotechnology executive with more than 20 years of leadership experience. He most recently served as President, CEO, and Board Member of Longboard Pharmaceuticals, where he led and transformed the Arena spinout into a leader in neurology and oversaw its $2.6 billion acquisition by H. Lundbeck A/S in 2024. Before his time at Longboard, Kevin Lind was EVP and CFO at Arena Pharmaceuticals, where he played a central role in its turnaround, including lucrative business development partnerships and execution of its spinout of Longboard in 2020. Over the course of his career, Kevin Lind has raised more than a billion dollars in capital to support innovative biotech companies. He began his career in investment banking at Lehman Brothers before joining TPG, where he focused on healthcare investing. In addition to his role with Avalo, Kevin Lind currently serves as Chairman of the Board of Apnimed, Inc.